Sphera Funds Management LTD. boosted its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 112.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 273,213 shares of the company's stock after purchasing an additional 144,817 shares during the quarter. Sphera Funds Management LTD. owned about 0.39% of ORIC Pharmaceuticals worth $2,205,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of ORIC. KLP Kapitalforvaltning AS bought a new position in ORIC Pharmaceuticals during the 4th quarter valued at about $50,000. BNP Paribas Financial Markets purchased a new position in shares of ORIC Pharmaceuticals during the fourth quarter valued at approximately $71,000. PNC Financial Services Group Inc. grew its stake in shares of ORIC Pharmaceuticals by 22.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after buying an additional 2,520 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in shares of ORIC Pharmaceuticals in the fourth quarter worth approximately $118,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of ORIC Pharmaceuticals by 1,048.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 14,661 shares of the company's stock worth $118,000 after acquiring an additional 13,384 shares during the last quarter. Institutional investors own 95.05% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on ORIC. Oppenheimer decreased their target price on ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Wedbush reissued an "outperform" rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research report on Thursday, March 20th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Monday, May 5th. Finally, JPMorgan Chase & Co. increased their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $19.17.
Check Out Our Latest Research Report on ORIC
ORIC Pharmaceuticals Stock Down 0.2%
Shares of NASDAQ ORIC traded down $0.01 during midday trading on Wednesday, reaching $5.66. 722,380 shares of the company's stock traded hands, compared to its average volume of 928,512. The company has a market cap of $402.43 million, a price-to-earnings ratio of -3.11 and a beta of 1.37. The stock's 50 day simple moving average is $5.52 and its 200-day simple moving average is $7.88. ORIC Pharmaceuticals, Inc. has a one year low of $3.90 and a one year high of $14.67.
ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. Equities analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.
About ORIC Pharmaceuticals
(
Free Report)
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Further Reading
Before you consider ORIC Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ORIC Pharmaceuticals wasn't on the list.
While ORIC Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
